DNA methylation plays an important and dynamic role in regulating gene expression. With the MethylationEPIC BeadChip, researchers can interrogate over 850,000 methylation sites quantitatively across the genome at single-nucleotide resolution. Multiple samples, including FFPE, can be analyzed in parallel to deliver high-throughput power while minimizing the cost per sample.
Powered by the industry-leading Infinium assay, the MethylationEPIC BeadChip is ideal for epigenome wide association studies (EWAS). It offers comprehensive, expert-selected coverage, including 99% of RefSeq genes, 95% of CpG islands, high coverage of enhancer regions, and other content categories. With >90% of the original content from the Infinium HumanMethylation450K covered, the MethylationEPIC kit supports the next generation.
The MethylationEPIC BeadChip combines comprehensive coverage and high-throughput capabilities, making it ideal for EWAS. Additional advantages include:
The MethylationEPIC BeadChip follows a user-friendly, streamlined workflow, enabling processing of up to 96 samples simultaneously from low sample input (as little as 250 ng).
Offering quantitative measurement at the single-CpG-site level for normal and FFPE samples, this methylation microarray offers powerful resolution for understanding epigenetic changes.
Click on the below to view products for each workflow step.
PCR-Free, low sample input (as low as 250 ng), kit using Infinium I and Infinium II assay chemistry technologies.
Supports high-throughput BeadChip processing, scanning hundreds to thousands of samples quickly and accurately.
Methylation array studies enable researchers to understand the functional mechanisms at work in complex disease. Illumina offers complementary solutions for researchers studying these disorders. Learn more about complex disease research.
Illumina array and sequencing solutions are ideal for detecting altered methylation patterns and epigenetic changes that provide insight into tumorigenic pathways and cancer progression. Learn more about cancer epigenetics.